News Search Results
Feb 26, 2026, 07:00 ET Matricelf Ltd. (TASE: MTLF) Reports 2025 Milestones and Outlines 2026 Strategic Roadmap Toward First-in-Human Spinal Cord Implantation
NESS ZIONA, Israel, Feb. 26, 2026 /PRNewswire/ -- Matricelf Ltd. (TASE: MTLF), a biotechnology company developing personalized regenerative therapies for spinal cord injury, today issued a shareholder update summarizing its 2025 achievements
More news about: Matricelf Ltd.
Feb 26, 2026, 06:30 ET Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced financial results for the
More news about: Immunic, Inc.
Feb 26, 2026, 06:30 ET Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Feb 26, 2026, 05:40 ET CJ BIO Publishes Clinical Study on BiomeNrich™ POST SZ075, a Postbiotic Ingredient Demonstrating Skin Improvement Benefits
density.Dual-Action Efficacy of BiomeNrich™ POST SZ075 for Skin Health A clinical study (n=111, 12 weeks, 500 mg/day) published in Food Science and Biotechnology (2025) confirms the dual functionality of BiomeNrich™ POST SZ075 in combating UV-induced wrinkles and enhancing hydration.I. Skin wrinkle
More news about: CJ CheilJedang
Feb 26, 2026, 03:15 ET genOway: Revolutionizing the Prediction of Antibody Therapies in Humans with Unique Mouse Model
(Belgium), a pioneer in Fc-engineering and FcRn biology; Innate Pharma (France), a leader in natural killer cell-based immunotherapies; and Vir Biotechnology (USA), focused on the development of immunotherapies; among other members. The group collaborated with VIB-Ghent University (Belgium), a leading
More news about: genOway
Feb 26, 2026, 03:15 ET genOway: Revolution der Vorhersage von Antikörpertherapien beim Menschen mit einem einzigartigen Mausmodell
FcRn-Biologie, Innate Pharma (Frankreich), ein führendes Unternehmen im Bereich der auf natürlichen Killerzellen basierenden Immuntherapien, und Vir Biotechnology (USA), das sich auf die Entwicklung von Immuntherapien konzentriert. Die Gruppe arbeitete mit der VIB-Ghent University (Belgien), einem führenden
More news about: genOway
Feb 26, 2026, 03:15 ET genOway:Revolucionando la predicción de terapias con anticuerpos en humanos con un modelo de ratón único
(Bélgica), pionera en ingeniería de Fc y biología de FcRn; Innate Pharma (Francia), líder en inmunoterapias basadas en células asesinas naturales; y Vir Biotechnology (Estados Unidos) enfocada en el desarrollo de inmunoterapias; entre otros miembros. El grupo colaboró con VIB-Ghent University (Bélgica), un instituto
More news about: genOway
Feb 26, 2026, 03:15 ET genOway : révolutionner la prédiction des thérapies à base d'anticorps chez l'humain grâce à un modèle murin unique
l'ingénierie Fc et de la biologie FcRn ; Innate Pharma (France), un leader des immunothérapies basées sur les cellules tueuses naturelles ; et Vir Biotechnology (États-Unis), spécialisé dans le développement d'immunothérapies, entre autres membres. Le groupe a collaboré avec le VIB-Gand (Belgique), un institut
More news about: genOway
Feb 26, 2026, 03:08 ET BPC Instruments reports results for 2025
AB (publ)BPC Instruments is a Swedish technology company developing analytical instruments for renewable bioenergy and environmental biotechnology, including biogas and biodegradability testing. The systems enable advanced testing with higher accuracy and consistency, while reducing the time
More news about: BPC Instruments AB
Feb 26, 2026, 00:00 ET New book 'The Oceans and Deserts Stock Exchange' proposes a market-driven solution to defeat climate change without economic collapse
"Tackling the Major Challenges of Our Times and Building The Selfless Economy." He graduated from The Johns Hopkins University with a master's in biotechnology enterprise and Entrepreneurship, an MBA from Michigan State University, and a bachelor's from the University of Illinois-Springfield. Mr. Matthew
More news about: Archway Publishing
Feb 25, 2026, 21:00 ET Argo Biopharma to Present Positive Phase II Interim Results of siRNA Therapeutic BW-20805 for HAE at the 2026 AAAAI Annual Meeting
HAE attacks with a significant and longer-lasting therapeutic effect.About Argo BiopharmaArgo Biopharma is a clinical-stage biotechnology company committed to developing next-generation RNAi therapeutics to provide better treatment options for patients worldwide. The company has established
More news about: Argo Biopharmaceutical Co., Ltd
Feb 25, 2026, 17:31 ET Tinnitus Treatment Landscape Set for Significant Market Upswing During Forecast Period (2026-2036) as Need for Effective Therapies Intensifies | DelveInsight
are expanding treatment options. Additionally, the launch of emerging therapies such as SPI-1005 (Sound Pharmaceuticals), GW-TT2/3/5 (Gateway Biotechnology), AC102 (AudioCure Pharma), NHPN-1010, OPI-001 (Otologic Pharmaceutics), and others will further propel the market growth.LAS
More news about: DelveInsight Business Research, LLP
Feb 25, 2026, 14:01 ET Six Rubin Rudman Partners Named to 2026 Legal 500 Boston Elite
family-owned business across a broad range of industries including construction, financial services, real estate, manufacturing, distribution, biotechnology, health care, and hospitality. With over 20 years of experience, Cordes has a diverse practice encompassing corporate, M&A, and finance matters.
More news about: Rubin Rudman
Feb 25, 2026, 12:25 ET HYDRINITY Accelerated Skin Science Announces Breakthrough Clinical Results Demonstrating the First "Hydrating Retinoid" with Zero Reported Irritation
integrity, establishing a new class of performance-driven skincare."This study marks an important milestone in the HYDRINITY mission to fuse biotechnology with advanced skincare," said Keith O'Briant, CEO of HYDRINITY. "To have our research published in the Journal of Cosmetic Dermatology underscores
More news about: HYDRINITY Accelerated Skin Science
Feb 25, 2026, 11:00 ET Dental Burs Market to Reach US$ 1,232.3 Million by 2033 on Growth of Dental Procedures and Technological Innovation
(Research Application, Drug Discovery, Disease Diagnostics, Other Applications), End Use (Research and Academic Institutes, Pharmaceutical & Biotechnology Companies, Diagnostic Laboratories, Others), and Regional Analysis for 2025-2032.
More news about: Persistence Market Research Pvt. Ltd.
Feb 25, 2026, 10:45 ET Age Related Macular Degeneration Market to Reach $16.2 billion by 2033, Globally, by 2034 at 5% CAGR: Allied Market Research
prevalence of dry age related macular degeneration among elderly populations. For instance, according to 2021 report by the National Center of Biotechnology Information (NCBI), it was estimated that about 90% of the population in the world suffer from dry age related macular degeneration.The
More news about: Allied Market Research
Feb 25, 2026, 09:40 ET Mahzi Therapeutics Announces First Patient Dosed in Phase 1/2 UNITE Study of MZ-1866 for Pitt Hopkins Syndrome
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 /PRNewswire/ -- Mahzi Therapeutics Inc., a clinical-stage biotechnology company developing precision therapies for neurogenetic disorders, today announced that the first patient has been dosed in its Phase 1/2 UNITE
More news about: MAHZI Therapeutics
Feb 25, 2026, 09:05 ET Tether Invests in Whop, World's Largest Internet Market, to Power Stablecoin Payments for the Next Generation of the Internet Economy
infrastructure, and real-world utility intersect.Its portfolio includes investments in artificial intelligence, financial services, energy, biotechnology, education, and digital media, as well as strategic stakes in industries such as commodities, remittances, and sports and entertainment. Tether
More news about: Whop
Feb 25, 2026, 09:05 ET Tether Invests in Whop, World's Largest Internet Market, to Power Stablecoin Payments for the Next Generation of the Internet Economy
infrastructure, and real-world utility intersect.Its portfolio includes investments in artificial intelligence, financial services, energy, biotechnology, education, and digital media, as well as strategic stakes in industries such as commodities, remittances, and sports and entertainment. Tether
More news about: Whop
Feb 25, 2026, 09:00 ET Foundation Fighting Blindness to Host Free Webinar on Regenerative Medicine Advances for Retinal Diseases
Research in Vision and Ophthalmology (ARVO).Jeff Stern, PhD, MD, is founder and chief medical officer of Luxa Biotechnology, where he is developing dry AMD treatment using RPE cell therapies. A retinal specialist with a PhD in biophysics and an MD in ophthalmology, Dr.
More news about: Foundation Fighting Blindness
Feb 25, 2026, 08:30 ET Halozyme to Participate in Upcoming Investor Conferences
than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen
More news about: Halozyme Therapeutics, Inc.
Feb 25, 2026, 08:07 ET P4ML Becomes Founding Member of Orphan Therapeutics Accelerator (OTXL) to Support Broader Global Access to Ultra-Rare Disease Treatments
pathway from early diagnosis to accelerated orphan therapy development.Supported by a world-class consortium of leading biopharma companies, biotechnology innovators, patient advocacy groups, and globally recognized academic and clinical institutions, BeginNGS further strengthens P4ML's position as
More news about: Orphan Therapeutics Accelerator
Feb 25, 2026, 08:00 ET Melodia Therapeutics Announces U.S. Patent Grant Covering MLD-151
increasingly competitive DPP1 inhibitor landscape."About Melodia Therapeutics AGMelodia Therapeutics AG is a clinical-stage biotechnology company based in Basel, Switzerland, focused on developing innovative therapies targeting neutrophil-driven inflammatory diseases.About
More news about: Melodia Therapeutics AG
Feb 25, 2026, 08:00 ET Parker Institute for Cancer Immunotherapy Announces Appointment of Bob Purcell as Chief Communications Officer
announced the appointment of Bob Purcell as Chief Communications Officer. With 25 years of experience in corporate and product communications for biotechnology, pharmaceuticals, diagnostics, and healthcare technology companies, Purcell will support PICI's efforts to drive innovation and collaboration in
More news about: Parker Institute for Cancer Immunotherapy
Feb 25, 2026, 08:00 ET Evogene Releases CEO Letter to Shareholders
operate across the full range of collaboration models.In human health, we are advancing multiple partnered drug discovery programs with biotechnology companies and academic institutions. Throughout 2025 and early 2026, ChemPass AI™ discovered development-candidate predictions that have progressed
More news about: Evogene